Home › NDC Lookup › RxCUI directory › RxCUI 205328

Lamivudine 100 MG Oral Tablet — RxCUI 205328

RxNorm drug concept · Semantic clinical drug
RxCUI 205328 Semantic clinical drug · SCD ● Current RxNorm concept 4 FDA products 8 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI205328
Official nameLamivudine 100 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known as3TC 100 MG Oral Tablet
FDA products mapped4
Package NDCs mapped8
Reported Medicaid activity (SDUD)1,448 prescriptions · 18 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Lamivudine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Lamivudine is not a cure, but it's an important part of treatment. It works by blocking a viral enzyme called reverse transcriptase, which HIV-1 and hepatitis B need to make copies...
  • What exactly does lamivudine do — is it a cure for HIV or hepatitis B?
  • This is a really important question. The lamivudine product for HIV-1 (like Epivir) contains a significantly higher dose than the lamivudine product made for hepatitis B. They look...
  • I've heard there are different lamivudine products. How do I know I have the right one?
📖 Read our full Lamivudine guide →

🕸️ Concept Web — How Lamivudine 100 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Lamivudine 100 MG Oral Tablet RxCUI 205328

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Lamivudine 68244
  2. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Lamivudine Oral Tablet 372563
    • Lamivudine Oral Product 1162819
    • Lamivudine Pill 1162820
    • Oral Tablet 317541
    • Oral Product 1151131
    • Pill 1151133
  3. Clinical & branded drugs 1

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Lamivudine 100 MG 317397

Showing up to 8 concepts per family — 8 of 8 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Lamivudine 100 MG SCDC · 317397
  • Lamivudine Oral Tablet SCDF · 372563
  • Lamivudine Oral Product SCDG · 1162819
  • Lamivudine Pill SCDG · 1162820

📦 FDA Products & Package NDCs

4 products · 8 package NDCs
8 package NDCs map to RxCUI 205328 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
31722-0001-02 20 BLISTER PACK in 1 CARTON (31722-001-02) / 10 TABLET, FIL... lamivudine Camber Pharmaceuticals, Inc. 2019-03-21
31722-0001-60 60 TABLET, FILM COATED in 1 BOTTLE (31722-001-60) lamivudine Camber Pharmaceuticals, Inc. 2019-03-21
31722-0752-06 600 TABLET, FILM COATED in 1 BOTTLE (31722-752-06) Lamivudine Camber Pharmaceuticals, Inc. 2014-01-02
31722-0752-31 10 TABLET, FILM COATED in 1 BLISTER PACK (31722-752-31) Lamivudine Camber Pharmaceuticals, Inc. 2014-01-02
31722-0752-32 100 TABLET, FILM COATED in 1 CARTON (31722-752-32) Lamivudine Camber Pharmaceuticals, Inc. 2014-01-02
31722-0752-60 60 TABLET, FILM COATED in 1 BOTTLE (31722-752-60) Lamivudine Camber Pharmaceuticals, Inc. 2014-01-02
51407-0866-60 60 TABLET, FILM COATED in 1 BOTTLE (51407-866-60) Lamivudine Golden State Medical Supply, Inc. 2025-06-09
60505-3250-06 60 TABLET, FILM COATED in 1 BOTTLE (60505-3250-6) Lamivudine Apotex Corp. 2014-01-03
Observed labelers: Camber Pharmaceuticals, Inc. (6) · Apotex Corp. (1) · Golden State Medical Supply, Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$9.6988
Range $9.6988–$9.6988 · middle 50% $9.6988–$9.6988 · 1 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.